Answers are grounded in this paper and cite their sources.
Artificial intelligence has considerable potential to support dermoscopic skin cancer assessment; however, class imbalance, heterogeneous lesion morphology, indistinct lesion boundaries, and imaging variability can limit model generalizability. This study presents DeepSkin, a segmentation-guided deep learning framework integrating lesion segmentation, generative augmentation, and lesion-focused classification. Dermoscopic images were first segmented using a bidirectional ConvLSTM-based U-Net (BCDU-Net), and the resulting lesion regions were used for region-of-interest (ROI) extraction. During classifier development, a conditional generative adversarial network (cGAN) generated class-conditioned synthetic lesion ROIs to increase training-data diversity and mitigate class imbalance. Real and synthetic training ROIs were subsequently used to train a fine-tuned VGG16 network for binary benign–malignant classification. The framework was developed using the ISIC 2016 dataset, comprising 900 training and 379 test images, and independently evaluated on the PH2 dataset. On ISIC 2016, DeepSkin achieved a Dice coefficient of 0.937 and an intersection over union (IoU) of 0.882 for lesion segmentation, together with a classification accuracy of 96.6% and a receiver operating characteristic area under the curve (ROC-AUC) of 0.981. Cross-dataset external evaluation on the independent PH2 dataset, conducted without retraining or fine-tuning, yielded a classification accuracy of 95%. Ablation analysis further demonstrated incremental performance improvements associated with preprocessing, segmentation-guided ROI extraction, and generative augmentation. Grad-CAM visualizations provided qualitative insight into image regions contributing to classification decisions. These findings suggest that integrating generative augmentation with segmentation-guided lesion classification can support accurate dermoscopic image analysis across independent datasets. Further evaluation using larger, diverse, multi-center and prospective clinical datasets is required to establish broader generalizability and clinical applicability.
No takes yet. Share an insight, caveat, or question.
Kavita Behara (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: